Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $114 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a price target of $114.
September 25, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Ultragenyx Pharmaceutical and maintained a price target of $114.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Ultragenyx Pharmaceutical. The maintained price target of $114 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100